NexTech3D.AI Corp.

NexTech3D.AI Corp.

NEXCF
NexTech3D.AI Corp.US flagOther OTC
0.08
USD
+0.00
- -
17.83MMarket Cap
2018 Y
2019 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2026 Y
TTM
Revenue per Share
- -
0.05
- -
0.26
0.08
0.03
0.04
0.02
0.01
0.01
Basic EPS, GAAP
- -
-0.11
- -
-0.23
-0.39
-0.27
-0.22
-0.05
-0.02
-0.02
Free Cash Flow per Basic Share
- -
-0.08
- -
-0.21
-0.3
-0.15
-0.12
-0.04
-0.02
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
0.11
0.12
0.29
0.27
0.11
-0.04
-0.05
-0.02
-0.02
Tangible Book Value per Share
0.05
- -
0.06
0.18
0.1
0.01
-0.04
-0.05
-0.02
-0.02
Basic Weighted Avg Shares
- -
44
- -
69
84
100
114
133
216
212
Sales/Revenue/Turnover
- -
2
- -
18
7
3
5
3
2
2
Operating Margin (%)
- -
-228.6
- -
-88.27
-479.86
-781.26
-385.86
-206.49
-130.72
-131.33
Depreciation Expense
- -
- -
- -
1
2
3
2
- -
- -
- -
Net Income, GAAP
- -
-5
- -
-16
-33
-27
-26
-7
-4
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-233.1
- -
-88.17
-488.08
-849
-507.87
-219.15
-171.37
-172.18
Working Capital
2
- -
3
14
9
3
-2
-5
-2
-2
LT Debt
- -
- -
- -
1
1
1
- -
- -
1
1
Total Equity
5
6
7
22
24
13
-2
-5
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-87.02
- -
-105.77
-139.89
-155.49
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'24
Dec'24
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
150
158
229
Market Capitalization
13
7
29

Working Capital

FRC

in mil. unless spec.
Sep'24
Dec'24
Mar'26
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
5
3
Payables & Accruals
4
5
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.06%
-50.88%
Free Cash Flow
- -
-10.99%
-13.48%
Net Income, GAAP
- -
-6.77%
-47.78%
Sales/Revenue/Turnover
- -
-25.57%
-33.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
- -
3
2026
- -
- -
- -
1
2

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
- -
-0.05
2026
- -
- -
-0.01
- -
-0.02

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Evan Gappelberg
Full Time Employees
172
Sector
Technology
Industry
Software - Application
Address
121 Richmond Street West Toronto ON Canada M5H 4B6
IPO Date
Nov 29, 2018
Business
Nextech3D.AI Corp. (OTCQX: NEXCF; CSE: NTAR; FSE: 1SS) provides AI-powered 3D modeling, augmented reality (AR), and event technology solutions for e-commerce, marketing, events, gaming, and manufacturing sectors worldwide. Founded in 2018 and headquartered in Toronto, Ontario, the company leverages patented 2D-to-3D conversion technology to generate photorealistic 3D models; offers ARway for no-code, no-beacon AR navigation and spatial computing; provides Toggle3D for generative AI-based CAD-to-4K 3D model conversion and publishing; delivers Map Dynamics for interactive event floor plans, exhibitor tools, and mobile apps; supplies Eventdex for event registration, badge printing, and blockchain-enabled NFT ticketing; and creates WebAR experiences for Amazon and other online retailers, alongside AI matchmaking and virtual product visualization services. Nextech3D.AI Corp. retains significant stakes in spun-out subsidiaries ARway.ai and Toggle3D.ai following their respective public listings in 2022 and 2023; recently entered a definitive agreement on December 1, 2025, to reacquire the remaining 60% of ARway.ai (valued at approximately C$3.2 million) via share exchange to integrate its AR navigation with Map Dynamics and streamline event operations; signed a binding letter of intent in September 2025 to acquire Eventdex for US$700,000 cash, enhancing registration capabilities and accelerating blockchain ticketing; and expanded 3D modeling into gaming and manufacturing markets while securing multiple new contracts and renewals in 2024-2025.

Company News

  • Nextech3D.ai Q1 revenue nearly doubles on event tech, services growth

  • Nextech3D.ai Delivers 101% Revenue Growth in Fiscal Q1 2027 as AI-Powered Event Platform Accelerates

  • Nextech3D.ai to Report Q1 Fiscal 2027 Financial Results and Provide Corporate Update on August 31, 2026

  • Traders shorten odds on October debut for Anthropic

  • Nextech3D.ai CEO Evan Gappelberg increases stake

  • Nextech3D.ai CEO Evan Gappelberg Purchases 250,000 Shares in Open Market

  • Citi upgrades Flutter after 13% share price slide

  • JD Sports appoints former IKEA boss Peter Agnefjäll as chair

  • Nextech3D.ai reports increase in new customer contracts through first seven months of 2026

  • Nextech3D.ai Expands Enterprise Customer Base, Generating $874,000 in New Contract Value, 160 New Customer Contracts and 92% Software Gross Margins in 2026

  • Nextech3D.ai reports increase in new customer contracts through first seven months of 2026

  • Nextech3D.ai signs LED display partnership with F2B Services

  • Nextech3D.ai Signs Strategic Partnership with F2B Services to Drive AI Software Adoption, Expand LED Display Opportunities and Accelerate Event Technology Growth

  • ARway Provides Update on Proposed Acquisition by Nextech3D.ai; Closing Expected in October 2026

  • Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares

  • Nextech3D.ai advances ARway acquisition as valuations confirmed

  • Nextech3D.ai CEO discusses ARway acquisition strategy - ICYMI

  • GSK hits three-month high as vaccines help earnings top forecasts

  • Nasdaq 100 enters correction as sell-off deepens, while Coke and Sherwin-Williams lead Dow

  • Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy